Abstracts tagged "Certolizumab pegol and pregnancy"

Abstract Number: 1409 • 2014 ACR/ARHP Annual Meeting
Pregnancy Outcomes after Exposure to Certolizumab Pegol: Updated Results from Safety Surveillance
Megan E. B. Clowse¹, Douglas C. Wolf², Frauke Förger³, John J. Cush⁴, Amanda Golembesky⁵, Laura Shaughnessy⁵, Dirk De Cuyper⁶, Kristel Luijtens⁷, Sarah Abbas⁸ and Uma Mahadevan⁹, ¹Rheumatology, Duke University Medical Center, Durham, NC, ²Atlanta Gastroenterology Associates, Atlanta, GA, ³Department of Rheumatology and Clinical Immunology and Allergology, Inselspital, University of Bern, Bern, Switzerland, ⁴Baylor Research Institute and Baylor University Medical Center, Dallas, TX, ⁵UCB Pharma, Raleigh, NC, ⁶Safety Patient Solutions BioBrands, UCB Pharma, Brussels, Belgium, ⁷UCB Pharma, Brussels, Belgium, ⁸UCB Pharma, Paris, France, ⁹UCSF Medical Center, San Francisco, CA
Background/Purpose Certolizumab pegol (CZP) is a PEGylated Fc-free anti-TNF approved for the treatment of RA, CD, psoriatic arthritis (PsA) and ankylosing spondylitis (AS). The objective…